Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-mor
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines ... with analysis and forecast of revenue. , Browse ... Market report, to get an idea of the ... of the segmentation in the Americas inorganic refrigerants ... figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Calif., June 23, 2011 Nile Therapeutics, Inc. (OTCQB: ... heart failure patients, today announced that it has completed ... securities consisting of an aggregate of 5,000,000 shares of ... 2,500,000 shares of common stock for aggregate gross proceeds ...
... 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... HIV/AIDS vaccines, announced today the opening of a third ... vaccine.  The Los Angeles-based AIDS Research Alliance (ARA) will ... site team: the AIDS Research Consortium of Atlanta and ...
... NEW YORK, June 22, 2011 Veredus Laboratories, a ... partner, STMicroelectronics (NYSE: STM ), today announced ... application that is able to detect 10 to 12 ... Escherichia coli (E. coli) responsible for the ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 2Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 4Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 2Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 3Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 4
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... from L-1 and Terminates Discussions ... ... ("L-1") (NYSE: ID ), a leading provider of identity solutions ... with Digimarc Corporation ("Digimarc") (Nasdaq: DMRC ). The,proposed transaction values ...
... Calif., June 30, 2008--In a breakthrough scientific study published ... of Sciences , scientists at the Burnham Institute for ... may be linked to Autism. The study demonstrated that ... in neural stem cells had smaller brains, fewer nerve ...
... College of Medicine and her colleagues discovered the first ... the intestines, causing diarrhea. The next step ... through which the enterotoxin interacts to cause diarrhea. ... be straightforward," said the professor of molecular virology and ...
Cached Biology News:Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 2Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 3Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 4Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 5Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 6Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 7Researchers link early stem cell mutation to autism 2Integrins as receptors give insight into rotavirus and diarrhea 2
Request Info...
Loading Buffer...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Request Info...
Biology Products: